Specialized proresolving lipid mediators in patients with coronary artery disease and their potential for clot remodeling
暂无分享,去创建一个
C. Serhan | N. Chiang | F. Welty | R. Colas | J. Dalli | Tarec K Elajami | Chia Nan | Jesmond Dalli
[1] T. Murohara,et al. Impact of omega-3 polyunsaturated fatty acids on coronary plaque instability: an integrated backscatter intravascular ultrasound study. , 2011, Atherosclerosis.
[2] C. Serhan,et al. D‐series resolvin attenuates vascular smooth muscle cell activation and neointimal hyperplasia following vascular injury , 2013, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[3] J. Haeggström,et al. Lipoxygenase and leukotriene pathways: biochemistry, biology, and roles in disease. , 2011, Chemical reviews.
[4] P. Ridker,et al. Aspirin triggers antiinflammatory 15-epi-lipoxin A4 and inhibits thromboxane in a randomized human trial. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[5] M. Toner,et al. Rapid Appearance of Resolvin Precursors in Inflammatory Exudates: Novel Mechanisms in Resolution1 , 2008, The Journal of Immunology.
[6] Roberto Marchioli,et al. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. , 1999 .
[7] P. Calder,et al. n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. , 2006, The American journal of clinical nutrition.
[8] T. Assimes,et al. A near null variant of 12/15-LOX encoded by a novel SNP in ALOX15 and the risk of coronary artery disease. , 2008, Atherosclerosis.
[9] L. Palmer,et al. Diminished lipoxin biosynthesis in severe asthma. , 2005, American journal of respiratory and critical care medicine.
[10] B. Leeb,et al. Intravenous application of omega-3 fatty acids in patients with active rheumatoid arthritis. The ORA-1 trial. An open pilot study , 2006, Lipids.
[11] Yu Lin,et al. Augmentation of Myocardial Production of 15-Epi-Lipoxin-A4 by Pioglitazone and Atorvastatin in the Rat , 2006, Circulation.
[12] G. Corrao,et al. Corrigendum to “Long-term effect of high dose omega-3 fatty acid supplementation for secondary prevention of cardiovascular outcomes: A meta-analysis of randomized, double blind, placebo controlled trials” [Atheroscler Suppl 14 (2) (2013) 243–251] , 2014 .
[13] D. Mozaffarian,et al. Plasma Phospholipid Long-Chain-3 Fatty Acids and Total and Cause-Specific Mortality in Older Adults A Cohort Study , 2013 .
[14] G. Ramadori,et al. Inflammation and Repair in Viral Hepatitis C , 2008, Digestive Diseases and Sciences.
[15] C. Serhan,et al. Resolvin D1 activates the inflammation resolving response at splenic and ventricular site following myocardial infarction leading to improved ventricular function. , 2015, Journal of molecular and cellular cardiology.
[16] Christian Weber,et al. Anti-Inflammatory Therapy in Chronic Disease: Challenges and Opportunities , 2013 .
[17] Yan Lu,et al. Resolvin E1 Metabolome in Local Inactivation during Inflammation-Resolution1 , 2008, The Journal of Immunology.
[18] C. Serhan,et al. Identification and signature profiles for pro-resolving and inflammatory lipid mediators in human tissue. , 2014, American journal of physiology. Cell physiology.
[19] Trevor A. Mori,et al. Short-term n-3 fatty acid supplementation but not aspirin increases plasma proresolving mediators of inflammation[S] , 2014, Journal of Lipid Research.
[20] S. Shuto,et al. Determination of ω-6 and ω-3 PUFA metabolites in human urine samples using UPLC/MS/MS , 2015, Analytical and Bioanalytical Chemistry.
[21] L. Cleland,et al. Dietary n-3 fats as adjunctive therapy in a prototypic inflammatory disease: issues and obstacles for use in rheumatoid arthritis. , 2003, Prostaglandins, leukotrienes, and essential fatty acids.
[22] C. Serhan,et al. Impaired Phagocytosis in Localized Aggressive Periodontitis: Rescue by Resolvin E1 , 2011, PloS one.
[23] Charles N. Serhan,et al. Pro-resolving lipid mediators are leads for resolution physiology , 2014, Nature.
[24] S. Bae,et al. Omega-3 polyunsaturated fatty acids and the treatment of rheumatoid arthritis: a meta-analysis. , 2012, Archives of medical research.
[25] A. Kantarcı,et al. Resolvin E1 (RvE1) Attenuates Atherosclerotic Plaque Formation in Diet and Inflammation-Induced Atherogenesis , 2015, Arteriosclerosis, thrombosis, and vascular biology.
[26] B. Samuelsson. Role of Basic Science in the Development of New Medicines: Examples from the Eicosanoid Field , 2012, The Journal of Biological Chemistry.
[27] R. Pande,et al. Aspirin-triggered lipoxin and resolvin E1 modulate vascular smooth muscle phenotype and correlate with peripheral atherosclerosis. , 2010, The American journal of pathology.
[28] Charles N. Serhan,et al. Lipid mediator class switching during acute inflammation: signals in resolution , 2001, Nature Immunology.
[29] M. Conte,et al. Systemic delivery of proresolving lipid mediators resolvin D2 and maresin 1 attenuates intimal hyperplasia in mice , 2015, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[30] Trevor A. Mori,et al. Resolvins D1, D2, and other mediators of self-limited resolution of inflammation in human blood following n-3 fatty acid supplementation. , 2012, Clinical chemistry.
[31] C. Serhan,et al. Atherosclerosis: evidence for impairment of resolution of vascular inflammation governed by specific lipid mediators , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[32] K. Swedberg. n-3 Fatty acids in cardiovascular disease. , 2011, The New England journal of medicine.
[33] C. Serhan,et al. Specific lipid mediator signatures of human phagocytes: microparticles stimulate macrophage efferocytosis and pro-resolving mediators. , 2012, Blood.
[34] L. Schwingshackl,et al. Effects of Olive Oil on Markers of Inflammation and Endothelial Function—A Systematic Review and Meta-Analysis , 2015, Nutrients.
[35] Trevor A. Mori,et al. n-3 Fatty acid supplementation and proresolving mediators of inflammation , 2016, Current opinion in lipidology.
[36] J. Uddin,et al. Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway , 2004, Nature Immunology.
[37] H. Ginsberg,et al. Safety and Efficacy of Omacor in Severe Hypertriglyceridemia , 1997, Journal of cardiovascular risk.
[38] B. McManus,et al. The Human Serum Metabolome , 2011, PloS one.
[39] G. Corrao,et al. Long-term effect of high dose omega-3 fatty acid supplementation for secondary prevention of cardiovascular outcomes: A meta-analysis of randomized, placebo controlled trials [corrected]. , 2013, Atherosclerosis. Supplements.
[40] D. Mozaffarian,et al. Circulating and Dietary Omega‐3 and Omega‐6 Polyunsaturated Fatty Acids and Incidence of CVD in the Multi‐Ethnic Study of Atherosclerosis , 2013, Journal of the American Heart Association.
[41] G. Caughey,et al. Reduction of cardiovascular risk factors with longterm fish oil treatment in early rheumatoid arthritis. , 2006, The Journal of rheumatology.
[42] S. Yusuf,et al. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. , 2012, The New England journal of medicine.
[43] L. Arterburn,et al. Distribution, interconversion, and dose response of n-3 fatty acids in humans. , 2006, The American journal of clinical nutrition.
[44] M. Hersberger,et al. The c.–292C>T promoter polymorphism increases reticulocyte-type 15-lipoxygenase-1 activity and could be atheroprotective , 2007, Clinical chemistry and laboratory medicine.
[45] Ira Tabas,et al. Inflammation and its Resolution as Determinants of Acute Coronary Syndromes , 2014, Circulation research.
[46] C. Serhan,et al. New endogenous anti-inflammatory and proresolving lipid mediators: implications for rheumatic diseases , 2007, Nature Clinical Practice Rheumatology.
[47] Anjali Sharma,et al. The Pro-Resolving Lipid Mediator Maresin 1 (MaR1) Attenuates Inflammatory Signaling Pathways in Vascular Smooth Muscle and Endothelial Cells , 2014, PloS one.
[48] GISSI-Prevenzione Investigators,et al. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial , 1999, The Lancet.
[49] E. Scoditti,et al. Mediterranean Diet Polyphenols , 2015 .
[50] J. Schwab,et al. Resolvin E1, an EPA-derived mediator in whole blood, selectively counterregulates leukocytes and platelets. , 2008, Blood.